Pacira Pharmaceuticals buy Barclays PLC
Start price
23.10.23
/
50%
€26.20
Target price
23.10.24
€53.51
Performance (%)
-30.53%
Price
24.07.24
€18.40
Summary
This prediction is currently active. Massive losses of -30.53% have been the result for the BUY prediction by Barclays_PLC. This prediction currently runs until 23.10.24. The prediction end date can be changed by Barclays_PLC at any time. Barclays_PLC has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Pacira Pharmaceuticals | -3.175% | -3.175% |
iShares Core DAX® | -0.612% | 0.567% |
iShares Nasdaq 100 | -3.018% | -3.205% |
iShares Nikkei 225® | -2.647% | 0.330% |
iShares S&P 500 | -1.932% | -1.126% |
Comments by Barclays_PLC for this prediction
In the thread Pacira Pharmaceuticals diskutieren
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Barclays PLC from $60.00 to $57.00. They now have an "overweight" rating on the stock.
Ratings data for PCRX provided by MarketBeat
Stopped prediction by Barclays_PLC for Pacira Pharmaceuticals
Pacira Pharmaceuticals
Start price
Target price
Perf. (%)
€26.80
08.05.24
08.05.24
€35.35
08.05.25
08.05.25
-33.21%
24.07.24
24.07.24